X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Divis Laboratories with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs TORRENT PHARMA - Comparison Results

DIVIS LABORATORIES    Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES TORRENT PHARMA DIVIS LABORATORIES/
TORRENT PHARMA
 
P/E (TTM) x 35.3 47.4 74.4% View Chart
P/BV x 6.9 6.4 106.5% View Chart
Dividend Yield % 0.7 0.8 82.2%  

Financials

 DIVIS LABORATORIES   TORRENT PHARMA
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-18
TORRENT PHARMA
Mar-18
DIVIS LABORATORIES/
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs1,1421,550 73.7%   
Low Rs5331,144 46.6%   
Sales per share (Unadj.) Rs146.6354.7 41.3%  
Earnings per share (Unadj.) Rs33.040.1 82.4%  
Cash flow per share (Unadj.) Rs38.464.2 59.8%  
Dividends per share (Unadj.) Rs10.0014.00 71.4%  
Dividend yield (eoy) %1.21.0 114.9%  
Book value per share (Unadj.) Rs222.8273.1 81.6%  
Shares outstanding (eoy) m265.47169.22 156.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x5.73.8 150.5%   
Avg P/E ratio x25.333.6 75.4%  
P/CF ratio (eoy) x21.821.0 104.0%  
Price / Book Value ratio x3.84.9 76.2%  
Dividend payout %30.334.9 86.6%   
Avg Mkt Cap Rs m222,318227,897 97.6%   
No. of employees `00010.814.7 73.2%   
Total wages/salary Rs m4,56111,353 40.2%   
Avg. sales/employee Rs Th3,616.04,083.0 88.6%   
Avg. wages/employee Rs Th423.8772.3 54.9%   
Avg. net profit/employee Rs Th814.9461.3 176.6%   
INCOME DATA
Net Sales Rs m38,91560,021 64.8%  
Other income Rs m1,1342,988 38.0%   
Total revenues Rs m40,04963,009 63.6%   
Gross profit Rs m12,61713,493 93.5%  
Depreciation Rs m1,4254,086 34.9%   
Interest Rs m133,085 0.4%   
Profit before tax Rs m12,3139,310 132.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,5432,529 140.1%   
Profit after tax Rs m8,7706,781 129.3%  
Gross profit margin %32.422.5 144.2%  
Effective tax rate %28.827.2 105.9%   
Net profit margin %22.511.3 199.5%  
BALANCE SHEET DATA
Current assets Rs m45,35152,623 86.2%   
Current liabilities Rs m6,50752,022 12.5%   
Net working cap to sales %99.81.0 9,960.3%  
Current ratio x7.01.0 689.0%  
Inventory Days Days127120 105.9%  
Debtors Days Days9576 124.8%  
Net fixed assets Rs m21,16085,016 24.9%   
Share capital Rs m531846 62.7%   
"Free" reserves Rs m58,62545,376 129.2%   
Net worth Rs m59,15646,222 128.0%   
Long term debt Rs m041,115 0.0%   
Total assets Rs m67,832142,432 47.6%  
Interest coverage x926.84.0 23,066.2%   
Debt to equity ratio x00.9 0.0%  
Sales to assets ratio x0.60.4 136.1%   
Return on assets %12.96.9 186.9%  
Return on equity %14.814.7 101.1%  
Return on capital %20.814.2 146.8%  
Exports to sales %00-   
Imports to sales %21.80-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m8,485NA-   
Fx inflow Rs m32,35914,580 221.9%   
Fx outflow Rs m9,0423,600 251.2%   
Net fx Rs m23,31710,980 212.4%   
CASH FLOW
From Operations Rs m7,7598,942 86.8%  
From Investments Rs m-4,783-47,070 10.2%  
From Financial Activity Rs m-3,14234,174 -9.2%  
Net Cashflow Rs m-166-3,655 4.5%  

Share Holding

Indian Promoters % 52.0 71.5 72.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.8 7.0 168.1%  
FIIs % 19.0 12.6 150.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 8.8 195.5%  
Shareholders   31,796 26,511 119.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   STRIDES PHARMA SCIENCE  ELDER PHARMA  ALEMBIC LTD  DR. DATSONS LABS  CADILA HEALTHCARE  

Compare DIVIS LABORATORIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 629 Points Higher; Realty and Auto Stocks Witness Buying(Closing)

Indian share markets continued their momentum throughout the day and ended the day on a strong note. Gains were largely seen in the realty sector, telecom sector and auto sector.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (2QFY19); Net Profit Up 92.3% (Quarterly Result Update)

Nov 9, 2018 | Updated on Nov 9, 2018

For the quarter ended September 2018, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 92.3% YoY). Sales on the other hand came in at Rs 13 bn (up 44.3% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

TORRENT PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 12.3% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (down 12.3% YoY). Sales on the other hand came in at Rs 19 bn (up 32.5% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Looking For Higher Interest Rates on Bank FDs? Read This!(Outside View)

Dec 5, 2018

Credit disbursement to the productive sectors of the economy such as infrastructure, engineering, food processing, textiles, and chemicals, among others is rising.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Dec 12, 2018 (Close)

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 8-QTR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS